Abstract
Background: Olmesartan medoxomil is an angiotensin II receptor blocker antihypertensive drug, which has low oral bioavailability because of poor aqueous solubility.
Objective: The objective of the present research is the development and optimization of Olmesartan medoxomil loaded self-micro emulsifying drug delivery system by D-optimal mixture design to improve its dissolution rate.
Methods: Solubility of Olmesartan medoxomil was determined in different oils, surfactants and cosurfactants. The pseudo ternary diagram was constructed for the identification of self-micro emulsification region. The D-optimal mixture design was employed for the optimization of SMEDDS formulations wherein the factors optimized were the concentration of oil (X1), surfactant (X2), and co-surfactant (X3) and the response was globule size (Y1) and dissolution rate (Y2). Developed selfmicroemulsifying drug delivery system was further assessed for self-emulsification time, drug loading capacity, transparency, globule size, in vitro dissolution and comparative in vitro dissolution testing of optimized formulation with pure medicament and commercially available product.
Results: The application of D-optimal mixture design resulted in 14 batches out of which F-5 was found to be the optimized batch which contained Olmesartan medoxomil (20 mg), Capmul MCM EP (23% v/v), Kolliphore EL (49% v/v) and Transcutol P (28% v/v) having globule size of 105 nm, 94.7% dissolution within 30 minutes. In vitro dissolution rate of the drug from SMEDDS was appreciably higher than that of pure drug and marketed products.
Conclusion: Olmesartan medoxomil self-microemulsifying drug delivery system was successfully developed and this approach could prove to be suitable for the improvement of the dissolution rate of BCS II class drugs.
Keywords: Bioavailability, D-optimal mixture design, SMEDDS, in vitro lipolysis, in vitro dissolution, Fasted State Stimulated Intestinal Fluids Media (FaSSIF).
Graphical Abstract
[http://dx.doi.org/10.2147/IJN.S211014] [PMID: 31308665]
[http://dx.doi.org/10.2174/2213476X05666180309160113]
[http://dx.doi.org/10.2174/2210303108666180313141956]
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[http://dx.doi.org/10.1016/j.jconrel.2015.03.020] [PMID: 25797561]
[http://dx.doi.org/10.1007/s11051-012-1345-z]
[http://dx.doi.org/10.1504/IJNT.2013.058120]
[http://dx.doi.org/10.1002/pat.4375]
[http://dx.doi.org/10.1590/S1984-82502011000300003]
[http://dx.doi.org/10.1016/j.ijpharm.2011.09.007] [PMID: 21944892]
[http://dx.doi.org/10.1016/j.biopha.2004.02.001] [PMID: 15082340]
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.038] [PMID: 17010543]
[http://dx.doi.org/10.5958/2231-5713.2016.00023.4]
[PMID: 27051286]
[http://dx.doi.org/10.3390/pharmaceutics10030078] [PMID: 29966249]
[http://dx.doi.org/10.1081/DDC-100101263] [PMID: 10789064]
[http://dx.doi.org/10.5530/phm.2015.6.2]
[http://dx.doi.org/10.4103/0975-7406.84463] [PMID: 21966167]
[http://dx.doi.org/10.1016/j.ejpb.2015.06.028] [PMID: 26159837]
[http://dx.doi.org/10.1155/2016/2364317] [PMID: 27294110]
[http://dx.doi.org/10.1208/s12248-014-9672-x] [PMID: 25274609]
[http://dx.doi.org/10.2174/156720109789000519] [PMID: 19534704]
[http://dx.doi.org/10.1021/mp300331z] [PMID: 23030411]